[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627671":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":54,"responsibleParty":337,"collaborators":31,"id":339,"slug":340,"hasResults":341,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":341,"sex":347,"minAge":348,"maxAge":349,"enrollmentInfo":350,"targetDuration":31,"studyType":353,"phases":354,"briefSummary":356,"conditions":357,"keywords":359,"overallStatus":362,"whyStopped":31,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":372},{"fullName":5,"class":6},"Chinese SLE Treatment And Research Group","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Vunakizumab group (Group Vuna I)","EXPERIMENTAL","Vanakizumab 240mg each 4 weeks subcutaneously (with an additional infection at day 15) for 52 weeks combined with glucocorticoid taken daily according to preset tapering protocol during same period",[13,14],"Drug: Vanakizumab","Drug: Prednisone",{"label":16,"type":10,"description":17,"interventionNames":18},"Ivarmacitinib group (Group Iva I)","Ivarmacitinib 8mg daily taken orally for 52 weeks combined with glucocorticoid taken daily according to preset tapering protocol during same period",[19,14],"Drug: Ivarmacitinib",{"label":21,"type":22,"description":23,"interventionNames":24},"Prednisone group (Group Pred)","ACTIVE_COMPARATOR","Prednisone taken daily according to preset tapering protocol for 52 weeks",[14],[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Vanakizumab","Vanakizumab 240mg each 4 weeks taken subcutaneously with an additional injection at day 15",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Ivarmacitinib","Ivarmacitinib 8mg daily taken orally",[16],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Prednisone","Prednisone taken daily according to preset tapering protocol",[16,21,9],[41],{"name":42,"affiliation":43,"role":44},"Xinping TIAN, M.D.","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",[46,50],{"name":42,"role":47,"phone":48,"phoneExt":31,"email":49},"CONTACT","+86-13691165939","tianxp6@126.com",{"name":51,"role":47,"phone":52,"phoneExt":31,"email":53},"Jing LI, M.D.","+86-13020061363","lijing6515@pumch.cn",[55,73,77,88,104,118,133,148,162,177,192,207,222,237,252,266,281,296,311,322],{"facility":56,"status":31,"city":57,"state":58,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Beijing Anzhen Hospital Capital Medical University","Beijing","Beijing Municipality","China","CN",{"type":62,"coordinates":63},"Point",[64,65],116.39723,39.9075,{"lat":65,"lon":64},[68,72],{"name":69,"role":47,"phone":70,"phoneExt":31,"email":71},"Lili PAN, M.D.","+86-13720021786","lilypansxmu@sina.com",{"name":69,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":43,"status":31,"city":57,"state":58,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":74,"geoPoint":76,"contacts":31},{"type":62,"coordinates":75},[64,65],{"lat":65,"lon":64},{"facility":78,"status":31,"city":57,"state":58,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":79,"geoPoint":81,"contacts":82},"Xuanwu Hospital Capital Medical University",{"type":62,"coordinates":80},[64,65],{"lat":65,"lon":64},[83,87],{"name":84,"role":47,"phone":85,"phoneExt":31,"email":86},"Yi ZHAO, M.D.","+86-13811038669","zy85070@xwhosp.org",{"name":84,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":89,"status":31,"city":90,"state":91,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"The First Affiliated Hospital of Sun Yat-sen University","Guanzhou","Guangdong",{"type":62,"coordinates":93},[94,95],113.37117,23.06828,{"lat":95,"lon":94},[98,102],{"name":99,"role":47,"phone":100,"phoneExt":31,"email":101},"Yujin YE, M.D.","+86-13600490868","yeyujin@mail.sysu.edu.cn",{"name":103,"role":44,"phone":31,"phoneExt":31,"email":31},"Yunjin YE, M.D.",{"facility":105,"status":31,"city":106,"state":91,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Shenzhen People's Hospital","Shenzhen",{"type":62,"coordinates":108},[109,110],114.0683,22.54554,{"lat":110,"lon":109},[113,117],{"name":114,"role":47,"phone":115,"phoneExt":31,"email":116},"Dongzhou LIU, M.D.","+86-13802257360","liu_dz2001@sina.com",{"name":114,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":119,"status":31,"city":120,"state":121,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"People's Hospital of Guangxi Zhuang Autonomous Region","Nanning","Guangxi",{"type":62,"coordinates":123},[124,125],108.31667,22.81667,{"lat":125,"lon":124},[128,132],{"name":129,"role":47,"phone":130,"phoneExt":31,"email":131},"Hanyou MO, M.D.","+86-13707730655","419459292@qq.com",{"name":129,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":134,"status":31,"city":135,"state":136,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Jiaozuo People's Hospital","Jiaozuo","Henan",{"type":62,"coordinates":138},[139,140],113.23914,35.23925,{"lat":140,"lon":139},[143,147],{"name":144,"role":47,"phone":145,"phoneExt":31,"email":146},"Dongyun YAO, M.D.","+86-13939199823","yaodongyun88@163.com",{"name":144,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":149,"status":31,"city":150,"state":136,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"The First Affiliated Hospital of Henan University of Science and Technology","Luoyang",{"type":62,"coordinates":152},[153,154],112.43684,34.67345,{"lat":154,"lon":153},[157,161],{"name":158,"role":47,"phone":159,"phoneExt":31,"email":160},"Xiaofei SHI, M.D.","+86-13663884080","sxf0379@126.com",{"name":158,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":163,"status":31,"city":164,"state":165,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Union Hospital Tongji Medical College of Huazhong University of Science and Technology","Wuhan","Hubei",{"type":62,"coordinates":167},[168,169],114.26667,30.58333,{"lat":169,"lon":168},[172,176],{"name":173,"role":47,"phone":174,"phoneExt":31,"email":175},"Xiaojing LIU, M.D.","+86-13072799445","xiaojing6163@163.com",{"name":173,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":178,"status":31,"city":179,"state":180,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Jiangsu Province Hospital","Nanjing","Jiangsu",{"type":62,"coordinates":182},[183,184],118.77778,32.06167,{"lat":184,"lon":183},[187,191],{"name":188,"role":47,"phone":189,"phoneExt":31,"email":190},"Yanyan WANG, M.D.","+86-13813892892","yongchy@sina.com",{"name":188,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":193,"status":31,"city":194,"state":195,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"The Second Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":62,"coordinates":197},[198,199],115.85306,28.68396,{"lat":199,"lon":198},[202,206],{"name":203,"role":47,"phone":204,"phoneExt":31,"email":205},"Xinwang DUAN, M.D.","+86-13970085678","13970085678@163.com",{"name":203,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":208,"status":31,"city":209,"state":210,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"The First Hospital of Jilin University","Ch’ang-ch’un","Jilin",{"type":62,"coordinates":212},[213,214],126.24667,42.74694,{"lat":214,"lon":213},[217,221],{"name":218,"role":47,"phone":219,"phoneExt":31,"email":220},"Zhenyu JIANG, M.D.","+86-15843079623","jlujzy@aliyun.com",{"name":218,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":223,"status":31,"city":224,"state":225,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"The First Hospital of China Medical University","Shenyang","Liaoning",{"type":62,"coordinates":227},[228,229],123.43278,41.79222,{"lat":229,"lon":228},[232,236],{"name":233,"role":47,"phone":234,"phoneExt":31,"email":235},"Chunling WU, M.D.","+86-13889116542","wuhuaguo7712@aliyun.com",{"name":233,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":238,"status":31,"city":239,"state":240,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"The First Affiliated Hospital of Baotou Medical College","Baotou","Neimenggu",{"type":62,"coordinates":242},[243,244],109.84389,40.6516,{"lat":244,"lon":243},[247,251],{"name":248,"role":47,"phone":249,"phoneExt":31,"email":250},"Yongfu WANG, M.D.","+86-18686198868","wyf18686198868@163.com",{"name":248,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":253,"status":31,"city":254,"state":240,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":255,"geoPoint":259,"contacts":260},"The Affiliated Hospital of Inner Mongolia Medical University","Hohhot",{"type":62,"coordinates":256},[257,258],111.65222,40.81056,{"lat":258,"lon":257},[261,265],{"name":262,"role":47,"phone":263,"phoneExt":31,"email":264},"Hongbin LI, M.D.","+86-13948536552","lhbwb73@gmail.com",{"name":262,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":267,"status":31,"city":268,"state":269,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"People's Hospital of Ningxia Hui Autonomous Region","Yinchuan","Ningxia",{"type":62,"coordinates":271},[272,273],106.27306,38.46806,{"lat":273,"lon":272},[276,280],{"name":277,"role":47,"phone":278,"phoneExt":31,"email":279},"Donggeng GUO, M.D.","+86-15769509687","guodonggeng@126.com",{"name":277,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":282,"status":31,"city":283,"state":284,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Sichuan Provincial People's Hospital","Chengdu","Sichuan",{"type":62,"coordinates":286},[287,288],104.06667,30.66667,{"lat":288,"lon":287},[291,295],{"name":292,"role":47,"phone":293,"phoneExt":31,"email":294},"Jing ZHU, M.D.","+86-18981838317","zhujingys@sina.com",{"name":292,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":297,"status":31,"city":298,"state":299,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"People's Hospital of Xinjiang Uygur Autonomous Region","Ürümqi","Xinjiang",{"type":62,"coordinates":301},[302,303],87.60046,43.80096,{"lat":303,"lon":302},[306,310],{"name":307,"role":47,"phone":308,"phoneExt":31,"email":309},"Kuerbanjiang Yimaiti, M.D.","+86-13999832117","kuerbanjiang211@qq.com",{"name":307,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":312,"status":31,"city":298,"state":299,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":313,"geoPoint":315,"contacts":316},"The First Hospital of Xinjiang Medical University",{"type":62,"coordinates":314},[302,303],{"lat":303,"lon":302},[317,321],{"name":318,"role":47,"phone":319,"phoneExt":31,"email":320},"Li LU, M.D.","+86-13999868690","luoli.6@163.com",{"name":318,"role":44,"phone":31,"phoneExt":31,"email":31},{"facility":323,"status":31,"city":324,"state":325,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":326,"geoPoint":330,"contacts":331},"The Second Affiliated Hospital of Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":62,"coordinates":327},[328,329],120.16142,30.29365,{"lat":329,"lon":328},[332,336],{"name":333,"role":47,"phone":334,"phoneExt":31,"email":335},"Jing XUE, M.D.","+86-13858121751","jingxue@zju.edu.cn",{"name":333,"role":44,"phone":31,"phoneExt":31,"email":31},{"type":338,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100627671","phase-4-efficacy-and-safety-of-vunakizumab-and-ivarmacitinib-in-the-treatment-of-active-takayasus-arteritis-100627671",false,"NCT07451665","Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","A Prospective, Open-label, Controlled, Multiple Centers Clinical Study of the Efficacy and Safety for Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis (TAK): The VIVA-TAK Ttrial","VIVA-TAK","Inclusion Criteria:\n\n* a. Adult patients (aged between 18-70 years) fulfilling the 2022 ACR\u002FEULAR classification criteria for TAK with new-onset or relapsing disease.\n* b. Presence of active disease despite treatment with gluccorticoids combined with a conventional synthetic or biologic immunosuppressive agent other than JAK inhibitors and IL-17 inhibitors, including new-onset patients and relapsed patients.\n\nPatient is considered to have active disease by the investigator is the patients meets at least two of the following three criteria: i) one or more clinical manifestations determined by the investigator to be due to active TAK; ii) one or more findings on imaging of progressive disease; or iii) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Clinical criteria included constitutional symptoms (fever, fatigue, and weight loss), musculoskeletal symptoms, vascular pain, neurological or visual symptoms, abdominal pain or angina, new or worsening limb claudication, loss of pulses, and worsening hypertension. Imaging criteria includes new vascular stenosis or aneurysms detected by ultrasound, computed tomography angiography (CTA), or magnetic resonance angiography.\n\nExclusion Criteria:\n\n* Participants are excluded from the study if any of the following criteria apply:\n\n  1. Medical Conditions\n\n     1. Severe disease from TAK for which urgent treatment with interventional vascular procedures or bypass surgery is considered necessary\n     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia, that is anticipated to need treatment during the study\n     3. Active hepatitis B or C virus infection\n     4. Active tuberculosis (Patients with latent tuberculosis infection could be enrolled with preventive therapy for tuberculosis flare)\n     5. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)\n     6. Poorly controlled diabetes\n     7. Patients with history of venous thrombosis\n     8. Upper GI bleeding within 3 months prior to enrollment\n     9. Uncontrolled heart failure\n     10. Refractory hypertension\n  2. Abnormal Laboratory Test Findings k. Serum liver enzyme elevation 3 times higher than the upper limits of normal range l. Severe renal function impairment with estimated glomerular filtration rate ≤ 30 ml\u002Fminute\u002F1.73 m2, calculated using the Modification of Diet in Renal Disease equation (doi:10.1056\u002FNEJMoa2102953)\n  3. Other Exclusion Criteria m. Females who are pregnant or intend to be pregnant during the time frame of the study n. History of treatment with JAKi or IL-17i. o. Any other medical, psychiatric, and\u002For social reason as determined by the investigator to be a contraindication for study participation","ALL","18 Years","70 Years",{"count":351,"type":352},180,"ESTIMATED","INTERVENTIONAL",[355],"PHASE4","This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.",[358],"Takayasu Arteritis (TAK)",[360,33,361],"Vunakizumab","randomized controlled trial","NOT_YET_RECRUITING","2026-02-28",{"date":365,"type":366},"2026-03-05","ACTUAL",{"date":368,"type":352},"2026-04-01",{"date":370,"type":352},"2029-03-31",{"name":5,"class":6},20]